Semaglutide sourced as a research compound from UNIK LAB is intended solely for in vitro and preclinical research use. It is not intended for human self-administration, veterinary use, or any application outside of a licensed research context. This article is provided for scientific and educational purposes only.
14.9% mean body weight reduction at 68 weeks. That figure from STEP-1 — followed, two years later, by a 20% reduction in cardiovascular events in the SELECT trial — rewrote what the research community thought a single peptide receptor could do.
Semaglutide's story is not simply one of incremental GLP-1 agonist development. It represents the compound that proved the GLP-1 receptor pathway extends well beyond glucose regulation — into appetite neuroscience, cardiovascular biology, and, increasingly, neurological research. The data trail is longer and more varied than any other compound in its class.
This guide covers semaglutide's molecular architecture, the mechanistic basis of GLP-1R activation, the key STEP and SUSTAIN datasets, SELECT cardiovascular outcomes, pharmacokinetics for research applications, and a systematic comparison with tirzepatide and retatrutide.
🔬 Related Research Compound
Retatrutide (LY3437943) — triple GLP-1/GIP/glucagon receptor agonist — is the subject of active Phase 3 research (TRIUMPH programme). A closely related compound in the GLP-1 agonist class, available research-grade at UNIK LAB.
Contents
- What Is Semaglutide?
- Molecular Architecture: The C18 Fatty Acid Strategy
- GLP-1R Mechanism: Central and Peripheral Pathways
- SUSTAIN Programme: Type 2 Diabetes Data
- STEP Programme: Obesity Data
- SELECT: Cardiovascular Outcomes Without Diabetes
- Semaglutide vs Tirzepatide vs Retatrutide: Full Comparison
- Pharmacokinetics: Injectable vs Oral Formulations
- Reconstitution Protocol for Research Studies
- Safety Profile in Published Trials
- Current Regulatory Status
- FAQ
What Is Semaglutide?
Semaglutide is a synthetic 31-amino acid analogue of native GLP-1 (glucagon-like peptide-1), developed by Novo Nordisk. Clinical designations: Ozempic® (T2D), Wegovy® (obesity), and Rybelsus® (oral T2D).
Core identifiers:
- CAS Number: 910463-68-6
- Molecular Formula: C₁₈₇H₂₉₁N₄₅O₅₉
- Molecular Weight: ~4,114 g/mol
- Sequence length: 31 amino acids (GLP-1 analogue)
- Half-life: ~7 days (subcutaneous), enabling once-weekly dosing
The sequence differs from native GLP-1(7-36)NH₂ at two key positions. Aib (α-aminoisobutyric acid) substitution at position 8 confers DPP-4 resistance. Arg³⁴ substitution further reduces protease susceptibility. The C18 fatty diacid chain conjugated to Lys²⁶ via a linker completes the albumin-binding architecture.
Semaglutide is the most extensively characterised GLP-1R agonist in the research literature, with Phase 3 datasets spanning T2D (SUSTAIN), obesity (STEP), cardiovascular outcomes (SUSTAIN-6 and SELECT), renal outcomes (FLOW), and emerging neurological research.
Molecular Architecture: The C18 Fatty Acid Strategy
Native GLP-1 has a two-minute plasma half-life. Making GLP-1 therapeutically useful required solving the half-life problem without destroying receptor affinity.
The DPP-4 resistance solution: Position 8 Aib substitution removes the primary DPP-4 cleavage site — necessary but not sufficient for a 7-day half-life.
The albumin-binding solution:The C18 fatty diacid chain attached to Lys²⁶ via a flexible linker creates reversible non-covalent albumin binding (Kd ~3–5 μM). At therapeutic concentrations, >99% of semaglutide is albumin-bound. Albumin (~66 kDa) is too large for efficient glomerular filtration — semaglutide bypasses renal clearance entirely. Terminal half-life: ~7 days.
Lipidation strategy comparison across the GLP-1 class:
| Compound | Fatty Acid Length | Half-life | Dosing |
|---|---|---|---|
| Liraglutide | C16 fatty acid | ~13 hours | Once daily |
| Semaglutide (sc) | C18 fatty diacid | ~7 days | Once weekly |
| Tirzepatide | C20 fatty diacid | ~5 days | Once weekly |
| Retatrutide | C20 fatty diacid | ~6 days | Once weekly |
GLP-1R Mechanism: Central and Peripheral Pathways
Pancreatic β-Cell Effects
GLP-1R activation follows the canonical cAMP/PKA pathway: semaglutide binds GLP-1R → Gαs dissociation → adenylyl cyclase activation → cAMP accumulation → PKA activation + Epac2 activation → phosphorylation of KATP channel components → enhanced glucose-stimulated insulin secretion, glucagon suppression (glucose-dependent).
The glucose-dependence is fundamental to the clinical safety profile. GLP-1R activation does not drive insulin secretion below euglycaemic concentrations — the mechanism is self-limiting, explaining why GLP-1 agonists have low intrinsic hypoglycaemia risk.
Central Appetite Suppression
GLP-1R is expressed in the hypothalamus (arcuate nucleus, paraventricular nucleus), brainstem (nucleus tractus solitarius, area postrema), and limbic structures. Central GLP-1R activation by semaglutide:
- Increases POMC neuron activity in the arcuate nucleus → α-MSH release → MC4R-mediated satiety signalling
- Reduces NPY/AgRP neuron activity → decreases orexigenic drive
- Activates the brainstem vagal circuit → enhanced satiety signalling
- Reduces the reward value of food intake via limbic GLP-1R effects — independently of satiety per se
SUSTAIN Programme: Type 2 Diabetes Data
SUSTAIN-6 (Marso SP et al., N Engl J Med, 2016, PMID 27633186): 3,297 adults with T2D and high CV risk. Semaglutide 0.5/1 mg vs placebo, ~2 years. Primary endpoint (MACE): HR 0.74 (95% CI 0.58–0.95) — 26% relative risk reduction. HbA1c: ~1.0–1.1% reduction. Weight: ~3–4.5 kg reduction. SUSTAIN-6 was the first signal that GLP-1R agonism might produce active cardiovascular benefit rather than merely the absence of harm.

STEP Programme: Obesity Data
STEP-1: Semaglutide 2.4 mg in Obesity Without T2D
Wilding JPH, Batterham RL et al. N Engl J Med, 2021, PMID 33567185.
1,961 adults, BMI ≥30 or ≥27 with comorbidities, no T2D. 68 weeks.
| Outcome | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Mean body weight change | −14.9% | −2.4% |
| % Achieving ≥5% weight loss | 86% | 32% |
| % Achieving ≥10% weight loss | 69% | 12% |
| % Achieving ≥15% weight loss | 51% | 5% |
| % Achieving ≥20% weight loss | 33% | 2% |
| Waist circumference change | −13.5 cm | −4.1 cm |
STEP-3: Semaglutide + Intensive Behavioural Therapy
Wadden TA et al. JAMA, 2021, PMID 33625476: 611 adults, 68 weeks, both groups receiving 30 IBT sessions. Semaglutide + IBT: −16.0% vs Placebo + IBT: −5.7%. The pharmacological effect was consistent despite the intensive lifestyle intervention background — GLP-1R and behavioural mechanisms operate through sufficiently distinct pathways to produce additive effects.
STEP-4: Weight Maintenance After Semaglutide Withdrawal
Rubino D et al. JAMA, 2021, PMID 33755728: 803 adults who completed 20-week semaglutide run-in (~10.6% weight loss), then randomised to continue semaglutide or switch to placebo. Placebo group regained ~6.9% body weight over 48 weeks; continuation group lost a further 7.9%. Total difference at 68 weeks: −15.2 percentage points.
Mechanistic implication: GLP-1R agonism provides pharmacologically-dependent weight loss requiring sustained receptor activation. Weight regain after cessation is rapid, underscoring the chronic nature of GLP-1R-mediated appetite regulation.
SELECT: Cardiovascular Outcomes Without Diabetes
Lincoff AM et al. N Engl J Med, 2023, PMID 37952131.
17,604 adults with BMI ≥27 kg/m², pre-existing cardiovascular disease, without type 2 diabetes. Semaglutide 2.4 mg vs placebo, median follow-up 39.8 months.
Primary results:
- MACE reduction: HR 0.80 (95% CI 0.72–0.90) — 20% relative risk reduction
- Absolute risk reduction: 1.5 percentage points (6.5% vs 8.0%)
- NNT: ~67 over ~3.3 years
- Weight reduction: ~9.4% semaglutide vs ~0.9% placebo
The SELECT population (no T2D) separates semaglutide's CV effect from its glucose-lowering effect. The 20% MACE reduction cannot be attributed to HbA1c improvement. Mechanistic hypotheses include: direct GLP-1R-mediated cardioprotection (GLP-1R expressed in cardiomyocytes and vascular endothelium), inflammation reduction, plaque stabilisation, and partial weight-mediated CV benefit.
For the triple agonist perspective on metabolic-cardiovascular interaction, see the Retatrutide Research Guide. For the dual agonist GIPR mechanism, see the Tirzepatide Research Guide.
Semaglutide vs Tirzepatide vs Retatrutide vs Liraglutide
↔ Scroll horizontally on mobile.
| Parameter | Semaglutide | Tirzepatide (LY3298176) | Retatrutide (LY3437943) | Liraglutide |
|---|---|---|---|---|
| CAS Number | 910463-68-6 | 2023788-19-2 | 2381089-83-2 | 204656-20-2 |
| Receptors Targeted | GLP-1R only | GLP-1R + GIPR | GLP-1R + GIPR + GCGR | GLP-1R only |
| Fatty Acid Chain | C18 diacid | C20 diacid | C20 diacid | C16 acid |
| Half-Life | ~7 days (sc) | ~5 days | ~6 days | ~13 hours |
| Max Weight Loss | −14.9% (68 wk, STEP-1) | −22.5% (72 wk, SURMOUNT-1) | −24.2% (48 wk, Phase 2) | −8.0% (56 wk, Phase 3) |
| CV Outcomes Data | Yes — SELECT (2023), SUSTAIN-6 (2016) | Pending (SURPASS-CVOT) | Not yet — Phase 3 ongoing | Yes — LEADER (2016) |
| Clinical Stage (2026) | Approved FDA + EMA (T2D, obesity, CV) | Approved FDA + EMA (T2D + obesity) | Phase 3 (TRIUMPH) | Approved FDA + EMA |
| Research Advantage | Broadest evidence base; SELECT CV data; oral formulation (Rybelsus); reference monoagonist | Largest Phase 3 dual agonist dataset; GIPR synergy mechanism | Strongest weight loss signal; GCGR axis; hepatic fat studies | Daily dosing for kinetic studies; longest track record |
| Research Limitation | No GIPR or GCGR component; lower efficacy ceiling vs dual/triple agonists | No GCGR component; CVOT pending | Phase 2 only; no CVOT data | Daily injection; lowest efficacy in class |
Pharmacokinetics: Injectable vs Oral Formulations
Subcutaneous (sc) formulation (Ozempic®, Wegovy®):
- Tmax: ~24–72 hours after sc injection
- Bioavailability (sc): ~89%
- Half-life: ~7 days
- Steady state: 4–5 weekly doses
- Volume of distribution: ~12.5 L
Oral formulation (Rybelsus®):
Oral semaglutide uses SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) as a GI absorption enhancer. Bioavailability: ~1% (must be taken fasting with ≤120 mL water, 30 min before food). Despite low bioavailability, once-daily 14 mg achieves therapeutic plasma levels. The oral formulation creates a distinct pharmacokinetic profile: Tmax ~1 hour, but the same ~7-day terminal half-life due to the albumin-binding architecture.
For in vitro research applications:
Semaglutide is used at nanomolar concentrations (EC50 at GLP-1R: ~0.01–0.1 nM) for receptor kinetics characterisation via cAMP accumulation assays in GLP-1R-expressing HEK293 cells. As a monoagonist, semaglutide provides a clean GLP-1R reference signal — used in parallel with tirzepatide to isolate GIPR-specific mechanistic contributions.
Reconstitution Protocol for Research Studies
Semaglutide from UNIK LAB is supplied as lyophilised powder, typically 5 mg vials.
- Solvent: Sterile water for injection or bacteriostatic water. For cell culture, use sterile PBS to avoid benzyl alcohol cytotoxicity.
- Volume: For 1 mg/mL: add 5 mL to 5 mg vial. For 0.5 mg/mL: add 10 mL.
- Technique: Add solvent slowly along vial wall. Do not inject onto lyophilised cake. Do not vortex. Gentle swirling 30–60 seconds.
- Storage:
- Bacteriostatic water: 2–8°C, up to 28 days
- Sterile water: −20°C, use within 7 days; avoid freeze-thaw cycling
- Aliquot into single-use volumes before freezing
For COA interpretation, see the UNIK LAB COA verification guide. For reconstitution protocols applicable to acylated peptides, see the UNIK LAB reconstitution guide.
Safety Profile in Published Trials
STEP programme adverse events (semaglutide 2.4 mg):
- Nausea: ~40–44% (most common; predominantly during dose escalation)
- Diarrhoea: ~30–35%
- Vomiting: ~24–26%
- Constipation: ~24–26%
- Decreased appetite: ~18–22%
All GI effects are dose-dependent, predominantly mild-to-moderate, and attenuate over time. Slow dose escalation (4-week titration protocol) substantially reduces incidence.
Notable safety data:
- Hypoglycaemia: Low intrinsic risk from GLP-1R monoagonism alone (glucose-dependent mechanism). Increased risk when combined with insulin or sulphonylureas.
- Heart rate: Modest increase (~2 bpm) — class effect of GLP-1R activation.
- Pancreatitis: Numerically low; no demonstrated causal increase in published Phase 3 data.
- Gallbladder: Increased cholelithiasis risk (~2–2.5x) associated with rapid weight loss — class effect.
- Thyroid C-cell: Rodent C-cell hyperplasia at suprapharmacological doses; human clinical significance unestablished.
Current Regulatory Status
As of April 2026:
- FDA: Ozempic® (sc T2D), Wegovy® (obesity), Rybelsus® (oral T2D), cardiovascular risk reduction in overweight/obese adults with CVD
- EMA: Ozempic® (T2D), Wegovy® (obesity), Rybelsus® (oral T2D)
- Health Canada: Ozempic®, Wegovy®
- Research use: Semaglutide as a research compound is used for institutional in vitro and preclinical studies. These applications are separate from the clinical approvals. Institutional compliance required.
Semaglutide is the canonical GLP-1R monoagonist reference standard. For researchers comparing GLP-1 class mechanisms, pairing semaglutide (monoagonist) with the tirzepatide dual agonist enables mechanistic isolation of GIPR contributions. The retatrutide triple agonist adds the glucagon receptor axis for hepatic fat and energy expenditure studies beyond what semaglutide or tirzepatide can address.
Research FAQ
What is semaglutide and how does it work?
Semaglutide is a synthetic 31-amino acid GLP-1 analogue with DPP-4 resistance (Aib at position 8) and C18 fatty diacid albumin binding extending the half-life to ~7 days. It activates GLP-1R via the cAMP/PKA pathway to stimulate glucose-dependent insulin secretion, suppress glucagon, delay gastric emptying, and reduce appetite via central hypothalamic and brainstem circuits. As a research compound, it provides a clean GLP-1R monoagonist reference standard.
What did the STEP-1 trial show?
STEP-1 (Wilding JPH et al., NEJM 2021, PMID 33567185): 1,961 adults with obesity without T2D, 68 weeks. Semaglutide 2.4 mg: −14.9% mean weight vs −2.4% placebo. 33% achieved ≥20% weight loss. Established the semaglutide efficacy ceiling that tirzepatide's SURMOUNT-1 subsequently exceeded (57% at ≥20% loss).
What is the significance of the SELECT trial?
SELECT (Lincoff AM et al., NEJM 2023, PMID 37952131): 17,604 adults with CVD, overweight/obese, no T2D, ~3.3 years. Semaglutide 2.4 mg reduced MACE by 20% (HR 0.80). Since the population had no diabetes, the CV benefit cannot be attributed to glucose-lowering — establishing GLP-1R agonism as producing cardioprotection independent of glycaemic effects.
What is the difference between semaglutide 0.5/1 mg and 2.4 mg?
Semaglutide 0.5/1 mg (Ozempic) targets T2D; 2.4 mg (Wegovy) targets obesity. Clear dose-response for weight loss: SUSTAIN doses gave ~4–7% weight reduction; STEP-1 at 2.4 mg gave ~14.9%. For research, dose selection depends on the endpoint studied.
How does the C18 fatty acid extend semaglutide's half-life?
The C18 fatty diacid chain at Lys²⁶ creates reversible albumin binding (Kd ~3–5 μM). The albumin-bound fraction (>99%) bypasses renal filtration (albumin is 66 kDa, too large for glomerular filtration) and resists DPP-4 degradation, extending the terminal half-life to ~7 days vs liraglutide's ~13 hours with a C16 chain.
What is semaglutide's regulatory status?
FDA and EMA approved as Ozempic® (T2D), Wegovy® (obesity), and Rybelsus® (oral T2D). Also FDA-approved for cardiovascular risk reduction post-SELECT. For in vitro and preclinical research, semaglutide is a research compound governed by institutional compliance rather than clinical approvals.
How does semaglutide compare to tirzepatide for research?
Semaglutide = reference GLP-1R monoagonist (GLP-1R only). Tirzepatide = dual GIP/GLP-1 agonist. Pairing both in experimental designs isolates GIPR-specific contributions. Semaglutide has superior CV outcome data (SELECT, SUSTAIN-6), oral formulation, and the broadest overall evidence base. Tirzepatide has greater weight loss efficacy and the unique GIPR synergy mechanism.
Available from UNIK LAB
Research Peptides
Research-grade Research Peptides · HPLC verified ≥98% · COA included · 48h EU/UK dispatch
